Table 4 Correlation of clinical parameters and achieving CR in the CLL patients receiving R-based immunochemotherapy (n = 44)
Characteristic | Number | CR (n, %) | P |
|---|---|---|---|
Age (years) | Â | Â | 0.263 |
   < 60 | 26 | 16 (61.5) |  |
   ≥ 60 | 18 | 8 (44.4) |  |
Rai risk stratification | Â | Â | 0.405 |
  Low or medium risk | 25 | 15 (60.0) |  |
  High risk | 19 | 9 (47.4) |  |
β2-MG (mg/L) |  |  | 0.003 |
   < 3.5 | 15 | 12 (80.0) |  |
   ≥ 3.5 | 18 | 5 (27.8) |  |
LDH (U/L) | Â | Â | 0.029 |
   < 220 | 30 | 20 (66.7) |  |
   ≥ 220 | 13 | 4 (30.8) |  |
ZAP-70 | Â | Â | 0.013 |
  Positive | 15 | 4 (26.7) |  |
  Negative | 11 | 8 (72.7) |  |
CD38 | Â | Â | 0.478 |
  Positive | 11 | 5 (45.5) |  |
  Negative | 24 | 14 (58.3) |  |
Genetic abnormalities | Â | Â | 0.038 |
  High risk | 15 | 5 (33.3) |  |
  Non high risk | 27 | 18 (66.7) |  |